Bispecific GD2 x B7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma
Erbe, A. K.; Feils, A. S.; Hampton, A.; Rosenkrans, Z. T.; Felder, M.; Wiwczar, J.; Gerhardt, D. J.; Bercher, M.; Wenke, B.; Haertle, C.; Heck, M.; VandenHeuvel, S. N.; Frankel, E.; Nielsen, M.; Spiegelman, D.; Tsarovsky, N.; Zaborek, J.; Rakhmilevich, A. L.; Hank, J. A.; Aluicio-Sarduy, E.; Engle, J.; Davis, J. H.; Glaser, B.; Subbotin, V.; Green, R.; Hernandez, R. T.; Hammer, B.; Sondel, P. M.
Show abstract
The current treatment for neuroblastoma involves an immunotherapy regimen that includes a monoclonal antibody that recognizes disialoganglioside (GD2), expressed at high levels on neuroblastoma. GD2 is not present on most normal tissues but is expressed on nerves. Thus, anti-GD2 treatment causes substantial, dose-limiting, neuropathic pain. B7-H3 is overexpressed on multiple tumor types, including neuroblastoma, with minimal normal cell expression and is absent on nerves. We designed a bispecific antibody (bsAb) that requires simultaneous binding of these two tumor antigens to achieve tight-binding of tumor cells. Our preclinical research shows that when compared to an anti-GD2 monospecific antibody, the GD2xB7-H3 bsAb has improved tumor specificity with similar efficacy and reduced toxicity. Since this bsAb does not bind to nerves, it may be possible to administer increased or additional doses beyond the tolerable dose of monospecific anti-GD2 antibodies, which could improve therapeutic efficacy and quality of life for patients with neuroblastoma.
Matching journals
The top 13 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Overcoming Tumor Heterogeneity by Ex Vivo Arming of T Cells Using Multiple Bispecific Antibodies 96%
- Oncolytic HSV-IL27 expression improves CD8 T cell function and therapeutic activity in syngeneic glioma models 95%
- GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma 95%
Similar papers in this journal
- Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancer 97%
- Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer 95%
- An antibody-tumor necrosis factor fusion protein that synergizes with oxaliplatin for treatment of colorectal cancer 95%
Similar papers in this journal
- Broadly Reactive Anti-VHH Antibodies for Characterizing, Blocking, or Activating Nanobody-Based CAR-T Cells 94%
- A Novel Bispecific Antibody CVL006 Superior to AK112 for Dual Targeting of PD-L1 and VEGF in Cancer Therapy 94%
- Development of a human glioblastoma model using humanized DRAG mice for immunotherapy 92%
Similar papers in this journal
- Probing the glioma micro-environment: analysis using biopsy in combination with ultra-fast cyclic immunolabeling 95%
- The Immune Response Against Cancer Is Modulated By Stromal Cell Fibronectin 94%
- Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutamate export and glutaminase 93%
Similar papers in this journal
- CYpHER: Catalytic extracellular targeted protein degradation with high potency and durable effect 95%
- Persister state-directed transitioning and vulnerability in melanoma 95%
- Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.